1. Albuvir, the First and Only New-Generation Anti-Viral Drug with Quick,
Direct Effect and a Wide Spectrum of Activity
Arthur Martynov, Ph.D, D. Sc. Boris Farber, Ph.D, D. Sc., Sophya Farber
American Medical Technologies, Inc and Noigel, Inc New York, USA
Albuvir
The Mechanism of the Penetration of a Viral
Genome through the Nuclear Membrane
Pharmacological Properties
of the Proposed Drugs
Clinical Data on Volunteers’
Use of Albuvir
ALBUVIR Contains more than 1 million partially acylated peptides. It effectively inhibits the process of nuclear importation of viral polynucleotides from those viruses that depend on the cell nucleus (FLU, HERPES VIRUSES, HIV/AIDS).
Albuvir, an anti-viral substance based on more than a million partially acylated peptides that is capable of effectively blocking the nuclear import/export system for viruses dependent on the cell nucleus. The drug’s effectiveness has been confirmed for more than 25 human and animal viruses; the drug is permitted for use in veterinary medicine.
The acylation of protein under various conditions leads to the formation of various derivatives: reactions in an alkaline medium leads to the formation of amides, while in an acidic medium, ethers are formed. This factor may also be used in a combined calculation of the maximum number of derivatives.
Since Albuvir is widely and successfully used in veterinary medicine, it was studied in volunteers with pathologies such as influenza, hepatitis C, combined infections of cytomegalovirus and herpes types 1 and 2, and the Epstein-Barr virus. For patients with the hepatitis C virus, the number of copies of the viral genome in the blood was controlled through the polymerase chain reaction method. After a month of use of the drug, a critical fall in this indicator from 40,000 copies/ml to 1,000-3,000 copies/ml was demonstrated. For the remaining pathologies, through the immunofluorescence method a sharp decline in the number of blood cells infected by the abovementioned viruses was demonstrated, which correlated with a positive clinical dynamic in all the volunteers. There was not one person for whom use of the drug was ineffective.
Thus at present, there are two drugs that have gone through the majority of pre-clinical studies: the anti-viral Albuvir (whose pharmacological properties are shown in the slide) and the anti-cancer drug Anticanum. Both drugs are non-toxic, non-allergenic, and highly active. Tolerance to the drug has not been found in a multitude of cultures.
Albuvir:
LD50=2880 mg/kg
ED50=25 mg/kg
Ti=115.2
T1/2=29 min
Application Method:
Peroral
Effective in the treatment of:
Influenza
Herpes Types 1 and 2
Cytomegalovirus Infection
Herpes Zoster Virus
Epstein-Barr Virus
Coronavirus
Many viruses that are dependent on the cell nucleus use the alpha-beta-importin system to transfer their DNA (or RNA, as in the influenza virus) into the cell nucleus and to remove from the nucleus the replicated RNA.
a-, b-importins
with Viral DNA
Genomic
Nuclear
DNA
Change of Molecular Charge to Negative
After Acylation (Succinylation,
Maleylation, Aconitylation) and
Neutralization after Acetylation
Nuclear
Membrane
Albuvir’s Mechanism of Action
Albuvir selectively bonds with signal peptides for nuclear import and blocks the penetration of viral DNA into the nucleus and the nuclear export of virion fragments.
Albuvir
Positive
Charge
Negative
Charge
a-, b-importins
with Viral DNA
Nuclear
Membrane
3rd International Conference on Drug Discovery and Therapy, February 2011